[HTML][HTML] Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer …
MJ Seckl, CH Ottensmeier, M Cullen… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
MJ Seckl, CH Ottensmeier, M Cullen, P Schmid, Y Ngai, D Muthukumar, J Thompson…
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.govPurpose Treating small-cell lung cancer (SCLC) remains a therapeutic challenge.
Experimental studies show that statins exert additive effects with agents, such as cisplatin, to
impair tumor growth, and observational studies suggest that statins combined with
anticancer therapies delay relapse and prolong life in several cancer types. To our
knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a
statin with standard-of-care for patients with cancer, specifically SCLC.
Experimental studies show that statins exert additive effects with agents, such as cisplatin, to
impair tumor growth, and observational studies suggest that statins combined with
anticancer therapies delay relapse and prolong life in several cancer types. To our
knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a
statin with standard-of-care for patients with cancer, specifically SCLC.
Abstract
Purpose
Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies delay relapse and prolong life in several cancer types. To our knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patients with cancer, specifically SCLC.
ncbi.nlm.nih.gov